Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-10
2011-10-25
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S131000
Reexamination Certificate
active
08044076
ABSTRACT:
The invention relates to phenyl derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
REFERENCES:
patent: 2007/0043104 (2007-02-01), Luthman et al.
patent: 2007/0270438 (2007-11-01), Bhattacharya et al.
patent: 2008/0249093 (2008-10-01), Colandrea et al.
patent: 2008/0306124 (2008-12-01), Albert et al.
patent: 2010/0063108 (2010-03-01), Bolli et al.
patent: 2010/0087417 (2010-04-01), Bolli et al.
patent: 2010/0168005 (2010-07-01), Bolli et al.
patent: 2010/0234346 (2010-09-01), Bolli et al.
patent: 2010/0331372 (2010-12-01), Bolli et al.
patent: 2011/0028448 (2011-02-01), Bolli et al.
patent: 2011/0028449 (2011-02-01), Bolli et al.
patent: 2011/0046170 (2011-02-01), Bolli et al.
patent: WO 91/15583 (1991-10-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 01/12627 (2001-02-01), None
patent: WO 02/068417 (2002-09-01), None
patent: WO 2003/062248 (2003-07-01), None
patent: WO 03/105771 (2003-12-01), None
patent: WO 2004/035538 (2004-04-01), None
patent: WO 2004/103279 (2004-12-01), None
patent: WO 2005/014525 (2005-02-01), None
patent: WO 2005/032465 (2005-04-01), None
patent: WO 2005/058848 (2005-06-01), None
patent: WO 2005/115382 (2005-12-01), None
patent: WO 2006/100631 (2006-09-01), None
patent: WO 2006/114400 (2006-11-01), None
patent: WO 2006/131336 (2006-12-01), None
patent: WO 2007/001973 (2007-01-01), None
patent: WO 2007/085451 (2007-08-01), None
patent: WO 2007/132307 (2007-11-01), None
patent: WO 2008/029370 (2008-03-01), None
patent: WO 2008/029371 (2008-03-01), None
patent: WO 2008/037476 (2008-04-01), None
patent: WO 2008/076356 (2008-06-01), None
patent: WO 2008/091967 (2008-07-01), None
Patani et al “Bioisosterism: A rational approach in drug design”, Chem. Rev. 1996, vol. 96, No. 8, pp. 3147-3176.
Kiryanov, A., et al., Synthesis of 2-Alkoxy-Substituted Thlophenes, 1,3-Thiazoles, and Related S-Heterocycles via Lawesson's Reagent-Mediated Cyclization under Microwave Irradiation: Applications for Liquid Crystal Synthesis, Journal of Organic Chemistry, 2001, pp. 7925-7929, vol. 66.
Chakraborti, et al., One-Pot Synthesis of Nitriles from Aldehydes Under Microwave Irradiation: Influence of the Medium and Mode of Microwave Irradiation on Product Formation, Tetrahedron, 1999, pp. 13265-13268, vol. 55.
Kaboudin, K., et al, One-Pot Synthesis of 1,2,4-Oxadiazoles Mediated by Microwave Irradiation under Solvent-Free Condition, Heterocycles, 2003, pp. 2287-2292, vol. 60, No. 10.
Brain, C.T., et al., Novel Procedure for the Synthesis of 1,3,4-Oxadiazoles from 1,2-diacylhydrazinos Using Polymer-Supported Burgess Reagent under Microwave Conditions, Tetrahedron Letters, 1999, pp. 3275-3278, vol. 40.
John, E.O., et al., Reactions of (Difluoroamino) Difluoroacetonitrile and (Difluoroamino) Difluoroacetamidoxime, Inorganic Chemistry, 1988, pp. 3100-3104, vol. 27.
Ecke, et al., Ortho-Alkylation of Aromatic Amines, Journal of Organic Chemistry, 1957, pp. 639-642, vol. 22.
Xu, B., et al., Acyclic Analogues of Adenosine Biphosphates as P2Y Receptor Antagonists: Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation, Journal of Medicinal Chemistry, 2002, pp. 5694-5709, vol. 45.
Gangloff, et al., Synthesis of 3,5-disubstituted-1,2,4-Oxadiazoles Using Tetrabutylammonium Fluoride as a Mild and Efficient Catalyst, Tetrahedron Letters, 201, pp. 1441-1443, vol. 42.
Gibson, M. (Editor), Pharmaceutical Preformuiation and Formulation, HIS Health Group, Englewood, CO, USA, (2001).
Greene, T.W., et al., Protective Groups in Organic Synthesis, 3rdEdition, Wiley New York, (1991).
Hla, et al., An Abundant Transcript Induced in Differentiating Human Endothelial Cells Encodes a Polypeptide with Structural Similarities to G-Protein-Coupled-Receptors, The Journal of Biological Chemistry, 1990, pp. 9308-9313, vol. 265, No. 16, The Medical Society for Biochemistry and Molecular Biology, Inc., USA.
Gould, P.L., Salt Selection for Basic Drugs, International Journal of Pharmaceutics, 1986, pp. 201-217, vol. 33.
Cui, J., et al., Design and Synthesis of Highly Constrained Factor Xa Inhibitors: Amidine-Substituted Bis(benzoyl)-[1,3]-diazepan-2-ones and Bis(benzylidene)-bis(gem-dimethyl)Cycloketones, Bioorganic Medicinal Chemistry, 2003, pp. 3379-3392, vol. 11.
Garcia, M.A., et al., Synthesis, Biological Evaluation, and Three-Dimensional Quantitative Structure—Activity Relationship Study of Small-Molecule Positive Modulators of Adrenomedullin, Journal of Medicinal Chemistry, 2005, pp. 4068-4075, vol. 48.
Meyer, E., et al., Synthesis of New 1,2,4- and 1,3,4-Oxadiazole Derivatives, Synthesis, 2003, pp. 899-905, No. 6.
Sato, N., et al., Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists, Bioorganic and Medicinal Chemistry Letters, 2004, pp. 1761-1764, vol. 14.
Kocienski, P.J., Protecting Groups, Thiome Stuggart, 1994.
Glennon, R.A., et al., β-Oxygenated Analogues of the 5-HT2A Serotonin Receptor Agonist 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, Journal of Medicinal Chemistry, 2004, pp. 6034-6041, vol. 47.
Poulain, R.F., et al., Parallel synthesis of 1,2,4-oxadiazoles from carboxylic acids using an improved, uronium-based, activation, Tetrahedron Letters, 2001, pp. 1495-1499, vol. 42.
Srivastava, R.M., et al., Synthesis of 3-Aryl-5-[Thien-3-YL Methyl]-1,2,4-Oxadiazoles, Synthetic Communications, 1999, pp. 1437-1450, vol. 29.
Gennaro, A.R. (Chairman of the Editorial Board and Editor)Remington, The Science and Practice of Pharmacy, 20thEdition, Philadelphia College of Pharmacy and Science.
Suzuki, T., et al., Synthesis of the Selective 5-Hydroxytryptamine 4 (5-HT4) Receptor Agonist (+)-(S)-2-Chloro-5-methoxy-4[5-(2-piperydylmethyl)-1,2,4-oxadiazol-3-yl]antline, Chem. Pharm. Bull., 1999, pp. 120-122, vol. 47.
Trapani, G., et al., Propofol Analogues. Synthesis, Relationships between Structure and Affinity at GABAA Receptor in Rat Brain, and Differential Electrophysiological Profile at Recombinant Human GABAA Receptors, Journal of Medicinal Chemistry, 1998, pp. 1846-1854, vol. 41.
Yan, L., et al., Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes, Bioorganic and Medicinal Chemistry Letters, 2006, pp. 3679-3683, vol. 16, No. 14.
Zhen, L., et al., Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P1) Receptor Agonists with Exceptional Selectivity against S1P2 and S1P, Journal of Medicinal Chemistry, 2005, pp. 6169-6173, vol. 48, No. 20.
U.S. Appl. No. 12/673,918.
Bolli Martin
Lehmann David
Mathys Boris
Mueller Claus
Nayler Oliver
Actelion Pharmaceuticals Ltd.
Cornet Jean
Fetterolf Brandon
Hoxie & Associates LLC
LandOfFree
Phenyl derivatives and their use as immunomodulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenyl derivatives and their use as immunomodulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenyl derivatives and their use as immunomodulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288702